Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
Mont-Saint-Guibert, Belgium – March 8, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 22, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link: Conference Registration (vevent.com). A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.nyxoah.com/events.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Novo Nordisk A/S - share repurchase programme6.5.2024 20:44:48 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 2.2 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 7 May 2024 and ending on 5 August 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme6.5.2024 20:40:01 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S’ 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day volume weighted average market price from 2 May 2024 to 6 May 2024 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results. Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.3% of the share capital and 77.4% of the votes. Following the transaction, Novo Holdings A/S owns 1,074,872,000 A shares of DKK 0.10 and 183,871,750 B shares of DKK 0.10, corresponding to 28.2% of the capital and 77.3% of the votes in Novo Nordisk A/S. The transaction is in line with th
Aktia Bank Abp: Anmälan om ändring av ägarandel i enlighet med kapitel 9 paragraf 10 i värdepappersmarknadslagen (Erkki Etolas ägarkontrollerade bolag)6.5.2024 19:30:00 CEST | Pressemelding
Aktia Bank Abp Börsmeddelande 6.5.2024 kl. 20.30 Aktia Bank Abp: Anmälan om ändring av ägarandel i enlighet med kapitel 9 paragraf 10 i värdepappersmarknadslagen (Erkki Etolas ägarkontrollerade bolag) Aktia Bank Abp har i enlighet med kapitel 9 paragraf 5 i värdepappersmarknadslagen emottagit anmälan av Erkki Etola, enligt vilken det av Erkki Etola kontrollerade bolaget Etola Group Oy:s innehav överskrider gränsen på 5 % av antalet aktier och röster i Aktia Bank Abp. De av Erkki Etola kontrollerade bolagens sammanlagda innehav av aktier och röster i Aktia Bank Abp överskrider inte flaggningsgränserna. Den information om aktieinnehav som presenteras i flaggningsmeddelandet återspeglar situationen efter de aktietransaktioner som genomfördes 6.5.2024. Det totala aktieinnehavet i Erkki Etolas kontrollerande bolag är oförändrat (9,75 %). Etola Group Oy:s aktieinnehav har redan överskridit gränsen på 5 % i och med aktieaffären 16.11.2023 och uppgick till 5,03 %. Detta överskridande har inte
Aktia Bank Plc: Disclosure under Chapter 9, Section 10 of the Finnish Securities Markets Act (Companies controlled by Erkki Etola)6.5.2024 19:30:00 CEST | Press release
Aktia Bank Plc Stock Exchange Release 6 May 2024 at 8.30 p.m. Aktia Bank Plc: Disclosure under Chapter 9, Section 10 of the Finnish Securities Markets Act (Companies controlled by Erkki Etola) Aktia Bank Plc has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Erkki Etola, according to which the holding of Etola Group Oy, the company controlled by Erkki Etola, exceeds the 5% threshold of the number of shares and voting rights in Aktia Bank Plc. The combined holdings of Erkki Etola's controlling companies of the number of shares and voting rights in Aktia Bank Plc do not exceed the flagging thresholds. The shareholding information presented in the disclosure statement reflects the situation after the share transactions executed on 6 May 2024. The total shareholding of Erkki Etola's controlling companies remains unchanged (9.75%). Etola Group Oy's shareholding has already exceeded the 5% threshold with the share transaction of 16
RevoluGROUP Canada Inc. Announces $1 Million Private Placement, Ex-CEO Marshall Outreach to Bernard Lonis Company Chairman6.5.2024 19:23:19 CEST | Press release
VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the "Company") announces a non-brokered private placement of up to 20,000,000 units at a price of $0.05 each, to raise gross proceeds of up to $1,000,000. Each unit will consist of one common share and one warrant (each, a "Warrant") exercisable to purchase one additional common share at a price of $0.10 each for a period of one (1) year from the date of issuance. The expiry of the Warrants may be accelerated at the sole discretion of the Company by written notice if the closing price for the Common Share on the TSX Venture Exchange shall be equal to or greater than CAD $0.15 for a minimum of ten (10) consecutive trading days. Ex-CEO Steve Marshall could satisfy a sizable lead order for the Private Placement, pending the successful approval and completion of the subsequent commitments as specified below. The private placement is subject to TSX Ventur